2019 a 'transformative year' for pharma M&A. Is that a good thing?
Big Pharma keeps getting bigger.
Fueled by the mega-mergers between Bristol-Myers Squibb and Celgene and between Allergan and AbbVie, the industry last year saw $350 billion worth of M&A, according to the new year-end report from the consultants at PwC. That’s a more than 50% increase on 2018.
“I kind of look at 2019 as a transformational year,” report author Glen Hunzinger told Endpoints News.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 72,900+ biopharma pros reading Endpoints daily — and it's free.